- Report
- January 2022
- 40 Pages
Saudi Arabia
From €1388EUR$1,500USD£1,168GBP
- Report
- March 2025
- 99 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- April 2024
- 119 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- July 2022
- 714 Pages
Global
From €2314EUR$2,500USD£1,946GBP
- Report
- January 2022
- 80 Pages
Africa
From €1851EUR$2,000USD£1,557GBP
- Report
- January 2022
- 40 Pages
Brazil
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
China
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
France
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
Germany
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
Ireland
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
Japan
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
Russia
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
South Korea
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
United States
From €1388EUR$1,500USD£1,168GBP
- Report
- January 2022
- 40 Pages
Vietnam
From €1388EUR$1,500USD£1,168GBP
- Report
- July 2022
- 274 Pages
Global
From €2391EUR$2,583USD£2,011GBP
€3415EUR$3,690USD£2,872GBP
- Report
- March 2022
- 225 Pages
Global
From €2313EUR$2,499USD£1,945GBP
€3304EUR$3,570USD£2,779GBP

The Ulcerative Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat a variety of gastrointestinal disorders. Ulcerative Colitis Drugs are used to treat the chronic inflammatory bowel disease of the same name. These drugs are typically administered orally or intravenously, and can be used to reduce inflammation, improve symptoms, and induce and maintain remission. Commonly prescribed Ulcerative Colitis Drugs include aminosalicylates, corticosteroids, immunomodulators, and biologics.
The Ulcerative Colitis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Pfizer, Takeda, Janssen, and UCB. Show Less Read more